Description
Immunotherapies for Neurologic Diseases, Volume 214 explores how neuroimmunotherapies intervene by targeting key molecules and pathways responsible for tissue damage in the central and peripheral nervous systems. The book details approved treatments that modulate T-cell signaling, antigen presentation, B cells and their trophic factors, autoantibodies, Fc receptors, complement, cytokines, and cell adhesion molecules. Each chapter includes clear explanations and illustrations, helping clinicians understand the mechanisms of these drugs in autoimmune neurological diseases. The volume serves as a practical and comprehensive guide, making complex therapeutic approaches accessible to medical professionals and students.The second section highlights the latest therapies for major autoimmune neurological diseases, offering step-by-step algorithms and escalation strategies for selecting optimal treatments. Controversies and uncertainties in therapy choices are discussed by leading experts, while additional chapters address emerging immunotherapeutic approaches for neurodegenerative diseases and the evolving concept of treating autoimmune pain. The book also covers practical applications of traditional immunosuppressants, IVIg, and targeted monoclonal antibodies, with dedicated chapters on conditions such as encephalitis, NMOSD, multiple sclerosis, and stiff person syndrome.- Summarizes and consolidates new research on immunotherapies for neurologic diseases- Identifies how immunotherapies work- Includes monoclonal antibodies or fusion proteins against B cells, T cells, and FcRn- Provides treatment algorithms and escalating therapies for common diseases- Highlights new agents in pipeline orin early trials
Table of Contents
SECTION I Introduction to neuro-immunotherapies1. Progress of neuroimmunotherapies: Witnessing an impressive success in the treatment of neurologic autoimmunitiesSECTION II Evolution of autoimmune neurology2. Autoimmune encephalitis, autoimmune dementias, and autoimmune psychotic disorders3. The history of paraneoplastic neurologic disorders of the CNS, PNS, and autonomic nervous systems: Perspective on the past toward a brighter futureSECTION III Basic principles of immune activation in neurologic diseases as related to targeted immunotherapies4. Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases5. Role of complement in neurologic autoimmunities: Why need to target complement activation for effective immunotherapy6. Paraneoplastic neurologic disorders and neurologic complications of immune checkpoint inhibitorsSECTION IV Immunotherapeutic agents in autoimmune neurologic diseases: Current and evolving biologics7. The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases8. Evolving targeted biologics against T cells, cytokines, and intracellular immune targets for multiple sclerosis with implications in other autoimmune neurologic diseases9. FcRn inhibitors: A new era in neurotherapeutics10. Intravenous immunoglobulin use in neurology11. Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptionsSECTION V Immunotherapies for specific neurologic diseases (how do I do it): A step-by step approach based on evidence-based indications with a view to the future12. Immunotherapies in progressive multiple sclerosis13. Disease-modifying therapy in pediatric multiple sclerosis14. Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease15. Immunotherapies on autoimmune encephalitis16. Immunotherapies in autoimmune movement disorders and cerebellar ataxia17. Immunobiology and immunotherapies in stiff-person syndrome and glutamic acid decarboxylase antibody-spectrum disorders: Present and future therapeutic prospects18. Immunotherapies on Guillain–Barré syndrome and other acute autoimmune neuropathies19. Immunotherapies in chronic immune-mediated neuropathies20. Autonomic nervous system autoimmunity and proposed immunotherapies21. Immunotherapy considerations for distal sensory-predominant and small-fiber peripheral neuropathies22. Immunotherapies in autoimmune neuromuscular junction disorders: Acute and chronic management23. Immunotherapies in autoimmune inflammatory myopathies: Rationale and therapeutic updates24. The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology
